BishtRef
Articles Journals Publishers Authors Subjects Most Cited New Papers Year Stats Open Access
journal article Open Access Nov 28, 2020

Autoimmune inner ear disease: A systematic review of management

Nathaniel K. Breslin Varun V. Varadarajan ORCID Eric S. Sobel Rex S. Haberman ORCID
Laryngoscope Investigative Otolaryngology Vol. 5 No. 6 pp. 1217-1226 · Wiley
View at Publisher Save 10.1002/lio2.508
Abstract
AbstractObjectivesThe study systematically reviewed the existing literature on the management of autoimmune inner ear disease (AIED).Study DesignSystematic review.MethodsWe performed a literature search of Embase, NCBI, Cochrane, and Web of Science databases from April 1990 to April 2020. Inclusion criteria included studies that were retrospective or prospective in nature evaluating the treatment of AIED with audiometric data measuring hearing outcomes during treatment. Hearing improvement was the primary study outcome and improvement in vestibular symptoms was the secondary study outcome.ResultsSixteen of 412 candidate articles were included in our study. Systemic steroid treatment is most commonly described. Alternative treatment modalities included intratympanic steroid treatment, methotrexate, cyclophosphamide, azathioprine, infliximab, etanercept, adalimumab, golimumab, methylprednisolone, rituximab, and anakinra.ConclusionSystemic corticosteroids are the first line treatment of AIED. Intratympanic steroids are a potential adjuvant or alternative treatment for patients who cannot tolerate or become refractory to steroid treatment. Steroid nonresponders may benefit from biologic therapy. Alternative treatment modalities including nonsteroidal immunosuppressants and biologics have been studied in small cohorts of patients with varying results. Prospective studies investigating the efficacy of biologic and nonsteroidal therapy are warranted.Level of Evidence2.
Topics

No keywords indexed for this article. Browse by subject →

References
55
[1]
Mccabe BF "Autoimmune sensorineural hearing loss" Ann Otol Rhinol Laryngol (2004) 10.1177/000348940411300703
[4]
Yoo TJ "β‐Tubulin as an autoantigen for autoimmune inner ear disease" Int Congr Ser (2003) 10.1016/s0531-5131(03)00814-8
[13]
Matsuoka AJ "Autoimmune inner ear disease: a retrospective review of forty‐seven patients" Audiol Neurotol (2013) 10.1159/000351289
[17]
Strum D "An update on autoimmune inner ear disease: a systematic review of pharmacotherapy" Am J Otolaryngol—Head Neck Med Surg (2020)
[22]
Lobo D "Intratympanic gadolinium magnetic resonance imaging supports the role of endolymphatic hydrops in the pathogenesis of immune‐mediated inner‐ear disease" J Laryngol Otol (2018) 10.1017/s0022215118000749
[23]
Zavod MB "Frequency of cochlear enhancement on magnetic resonance imaging in patients with autoimmune sensorineural hearing loss" Arch Otolaryngol—Head Neck Surg (2000) 10.1001/archotol.126.8.969
[24]
Garda‐Berrocal JR "Deficiency of naive T cells in patients with sudden deafness" Arch Otolaryngol—Head Neck Surg (1997) 10.1001/archotol.1997.01900070056009
[25]
Zeitoun H "Corticosteroid response and supporting cell antibody in autoimmune hearing loss" Arch Otolaryngol—Head Neck Surg (2005) 10.1001/archotol.131.8.665
[31]
Zibelman M "Autoimmune inner ear disease in a melanoma patient treated with pembrolizumab" J Immunother Cancer (2016) 10.1186/s40425-016-0114-4
[32]
Stork CM (2014)
[35]
Matteson EL "Open trial of methotrexate as treatment for autoimmune hearing loss" Arthritis Rheum (2001) 10.1002/1529-0131(200104)45:2<146::aid-anr167>3.0.co;2-i
[36]
Salley J "Methotrexate in the management of immune mediated cochleovestibular disorders: clinical experience with 53 patients" J Rheumatol (2001)
[41]
Matteson EL "Etanercept therapy for immune‐mediated cochleovestibular disorders: a multi‐center, open‐label, pilot study" Arthritis Care Res (2005) 10.1002/art.21179
[42]
Van Wijk F "Local perfusion of the tumor necrosis factor α blocker infliximab to the inner ear improves autoimmune neurosensory hearing loss" Audiol Neurotol (2006) 10.1159/000095897
[44]
Kasi PM "Clinical review: serious adverse events associated with the use of rituximab – a critical care perspective" Crit Care (2012) 10.1186/cc11304

Showing 50 of 55 references

Cited By
42
Disease-Modifying Antirheumatic Drugs in the Treatment of Autoimmune Inner Ear Disease: A Systematic Review and Meta-Analysis of Auditory and Vestibular Outcomes

Tamar M. Gordis, Sunny R. Shah · 2023

Otology &amp; Neurotology
Metrics
42
Citations
55
References
Details
Published
Nov 28, 2020
Vol/Issue
5(6)
Pages
1217-1226
License
View
Authors
N
Nathaniel K. Breslin

University of Florida College of Medicine Gainesville Florida USA

V
Varun V. Varadarajan

Department of Otolaryngology—Head and Neck Surgery The Ohio State University Columbus Ohio USA

E
Eric S. Sobel

Department of Medicine, Division of Rheumatology and Clinical Immunology University of Florida Gainesville Florida USA

R
Rex S. Haberman

Department of Otolaryngology—Head and Neck Surgery University of Florida Gainesville Florida USA

Cite This Article
Nathaniel K. Breslin, Varun V. Varadarajan, Eric S. Sobel, et al. (2020). Autoimmune inner ear disease: A systematic review of management. Laryngoscope Investigative Otolaryngology, 5(6), 1217-1226. https://doi.org/10.1002/lio2.508
Related

You May Also Like

Odontogenic sinusitis: A review of the current literature

Ryan E. Little, Christopher M. Long · 2018

143 citations

Olfactory epithelium: Cells, clinical disorders, and insights from an adult stem cell niche

Rhea Choi, Bradley J. Goldstein · 2018

104 citations

Specimen mapping in head and neck cancer using fluorescence imaging

Nutte Teraphongphom, Christina S. Kong · 2017

46 citations

Emerging options in immune‐mediated hearing loss

Hitomi Sakano, Jeffrey P. Harris · 2018

41 citations

Presence of exacerbating factors of persistent perceptual‐postural dizziness in patients with vestibular symptoms at initial presentation

Kayoko Kabaya, Hitomi Tamai · 2022

29 citations